Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Genetic Testing For Tamoxifen, Warfarin, Plavix Lacks “Clear Value,” Express Scripts Says

Executive Summary

Express Scripts’ caution about the cost effectiveness of some genetic testing could hint at how interested it will be in continuing the pharmacogenomic programs sponsored by former rival PBM Medco, which Express acquired in early April.

You may also be interested in...



Express Scripts Realignment Identifies Non-Core Businesses

Express Scripts is “looking at strategic alternatives” for some of its non-core businesses, which include international ventures, UBC and PolyMedica.

Express Scripts-Medco Merger Closes With No Divestitures Needed

The FTC voted in a split 3-1 vote to close its investigation and allow Express Scripts’ $29.1 billion acquisition of rival PBM Medco to proceed.

Medco, AssureRx Partner In Trial To Improve Psychotropic Medication Adherence Through Genetic Testing

Medco does not expect results to alter reimbursement decisions, but to offer another tool to help physicians make prescribing decisions.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS054407

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel